Source comparison
Dosage Protocols: With DAC vs Without DAC
CJC-1295 with DAC research protocols typically use 1–2 mg per week as a single subcutaneous injection. This form was originally developed for growth hormone deficiency treatment requiring once-weekly dosing convenience. The albumin-binding DAC extends eliminat
This comparison does not assign a generated winner or score.
- CJC-1295 with DAC research protocols typically use 1–2 mg per week as a single subcutaneous injection. This form was originally developed for growth hormone deficiency treatment requiring once-weekly dosing convenience. The albumin-binding DAC extends elimination half-life to approximately 6–8 days, meaning serum levels accumulate across weekly injections until reaching steady-state around week three. At this point, trough levels remain elevated throughout the week, creating continuous GHRH receptor stimulation.
- The trade-off: research from Monash University found that continuous GHRH receptor activation downregulates receptor density by 30–50% within four weeks, requiring progressively higher doses to maintain the same IGF-1 response. Additionally, the inability to clear the peptide between doses means any adverse effects. Joint stiffness, carpal tunnel symptoms, glucose intolerance. Cannot be immediately reversed by skipping an injection. Our experience reviewing protocols across research institutions shows that with-DAC forms produce the most dramatic early IGF-1 spikes (200–300 ng/mL increases in week one) but also the highest rate of metabolic adaptation by week eight.
- CJC-1295 without DAC. The modified GRF 1-29 variant. Requires 2–3 injections weekly at 100–300 mcg per dose. Because it clears within 30 minutes, each injection produces a discrete GH pulse lasting 90–120 minutes before returning to baseline. This allows the natural somatostatin-mediated pulse termination to occur, preserving the hypothalamic-pituitary feedback loop. Titration begins at 100 mcg to assess individual GH responsiveness (some researchers show 3× IGF-1 elevation at this dose, others barely move) and increases by 50–100 mcg every two weeks based on serum IGF-1 levels and subjective recovery markers.
- Timing matters more with the without-DAC form. Administering during an endogenous GH pulse window. Early morning fasted or immediately post-resistance training. Amplifies the natural pulse rather than creating an artificial one. Research from the University of North Carolina demonstrated that Modified GRF 1-29 administered at 5 AM during the physiological pulse produced 4.2× baseline GH elevation, while the same dose at 2 PM (during a naturally suppressed window) produced only 1.8× elevation.